Torsdag 21 November | 14:40:13 Europe / Stockholm

Prenumeration

2024-11-18 10:55:00

Redeye comments on Cantargia’s Q3 report, the proposed rights issue of SEK170m and the plans to focus on IL1RAP-high patients.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/